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ABSTRACT
Objectives: Non-adherence to asthma medication can lead to lower disease control and
asthma exacerbations that may be fatal. This survey assessed the attitude and expectations of
Belgian asthma patients towards their treatment.
Methods: This cross-sectional survey was conducted between June 2015 and February 2016
in 70 Belgian pharmacies. Participants completing the survey had to be ≥15 years, diagnosed
with asthma, and on inhaled corticosteroid-based treatment. The analysis included 80 com-
pleted questionnaires.
Results: Participants comprehended well that controller drugs are intended to prevent the
occurrence of asthma symptoms and complications, and their long-term daily use should be
maintained. Twenty seven percent of participants indicated fear of side eﬀects concerning
long-term daily use of a controller inhaler. Participants had a good understanding that quick-
relief drugs are intended to (quickly) relieve asthma symptoms and do not need to be used
on a systematic, daily basis. Out of 73 participants on long-term controller drugs, 33 (45%)
were ‘non-adherent’ (used less frequently than prescribed). Suboptimal adherence to main-
tenance treatment appeared to increase nightly awakenings and the risk of restrictions in
activities due to asthma. Out of 54 participants with available quick-relief drug adherence
data, 18 (33%) were non-adherent (used their quick-relief drug more frequently than
prescribed).
Discussion: This survey conﬁrms suboptimal adherence to maintenance controller therapy
and overuse of short-acting reliever medications among Belgian patients, which aﬀects
asthma control and quality of life. A substantial proportion of patients expressed fear about
their chronic therapy, indicating the need for patient education about their disease and its
management.
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Introduction
Asthma is a chronic inﬂammation of the airways. It is
estimated that more than 300 million people are
aﬀected worldwide, with prevalence increasing over
the last few decades [1,2]. Daily inhaled corticoster-
oids (ICS) remain the cornerstone of asthma manage-
ment according to all guidelines [3]. ICS are, to a large
extent, responsible for the observed reduction in
asthma morbidity and mortality over the past two
decades [4,5]. While controller medications are used
for maintenance treatment, quick-relief drugs are
intended to oﬀer immediate relief [6]. Ultimately,
eliminating the dependency on reliever medication
remains one of the goals of asthma management.
Despite the proven eﬃcacy of ICS therapy, adher-
ence to daily ICS remains suboptimal at approxi-
mately 50% or lower [7,8]. Reasons for poor patient
adherence to ICS include side eﬀects, fear of side
eﬀects, forgetfulness, or inconvenience of regular
medication use [9]. Additionally, inadequate percep-
tions of asthma control may play a role; asthma
patients, for example, may not realize the importance
of using ICS on a daily basis even in the absence of
symptoms. Causes commonly cited by patients for
suboptimal adherence are the abatement of symp-
toms, forgetting to take medication, and fear of
potential side eﬀects of ICS [10–13].
Suboptimal adherence may have signiﬁcant conse-
quences for the patient, such as poor asthma control,
exacerbations, hospitalizations, a decline in lung func-
tion, or a decreased quality of life [14]. Non-adherence
to ICS has also been reported in a signiﬁcant propor-
tion of patients with diﬃcult-to-control asthma [15]. It
is critical to know if poor asthma control is due to
non-adherence to the treatment; otherwise, a patient
with uncontrolled asthma may be unnecessarily
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stepped up to other (and often more expensive)
therapies. Thus, continuous eﬀorts aimed at improv-
ing adherence, especially with ICS and inhaler treat-
ments, are warranted. A literature review on hindering
factors inﬂuencing adherence to asthma treatment
among adolescents revealed that the plethora of
parameters involved complicate reﬁnement of the
situation [16]. A better understanding of patients’
behavior, motives, beliefs, and perceptions towards
adherence to asthma treatment remains key to ulti-
mately achieve better self-management.
Thus, the objectives of the survey were to assess
the attitude of Belgian asthma patients towards their
treatment and expectations concerning their medica-
tions, the adherence to controller and quick-relief
therapy, and its association with limitations in activ-
ities and night awakenings.
Material and methods
Study design
This cross-sectional survey was conducted in Belgium
between June 2015 and February 2016. Seventy phar-
macies across the three regions (Flanders, Wallonia,
and Brussels-Capital) were randomly selected from
a complete list of Belgian pharmacies. Each pharmacy
was asked to distribute 25 questionnaires with
a target of 20 completed questionnaires. The pharma-
cists gave the questionnaire to the participants col-
lecting ICS-based treatment for asthma. Participation
to the survey was voluntary and pharmacies had the
right to withdraw from the study at any time.
The questionnaire had to be ﬁlled in by the parti-
cipant; pharmacists or other pharmacy staﬀ could not
be involved in the completion of the form.
Participants could either ﬁll in the hard copy ques-
tionnaire on site or at their convenience and return
the completed form back to the pharmacy. The parti-
cipants’ anonymity was ensured and no personally
identiﬁable information (such as name, address) was
collected. To ensure complete data privacy, question-
naires from all sites were pooled together before
encoding.
Data entry was done in duplicate and was system-
atically compared for accuracy. Questionnaires with
incomplete data related to the objectives of the sur-
vey were excluded from the survey.
The study was approved by the central Ethics
Committee of the Universitair Ziekenhuis Gent and
received a favorable opinion in writing by the
College of Pharmacists.
Study participants
Participants had to be 15 years of age or older, have
a diagnosis of asthma, and use ICS-based treatment to
control his/her asthma symptoms, at the time of com-
pleting the survey. Potential participants had to indi-
cate their diagnosis of asthma on the questionnaire;
persons suﬀering from chronic obstructive pulmonary
disease (COPD) were not included.
Study objectives
The objectives of this survey were to assess the atti-
tude of asthma patients towards their treatment and
their treatment expectations, the adherence to con-
troller and quick-relief therapy, and its association
with limitations in activities and night awakenings.
Questionnaire design
The questionnaire was available in two local lan-
guages (Dutch and French) and divided in three sec-
tions to collect the following information: (1) general
data: questions regarding diagnosis, gender, year of
birth, and smoking status; (2) questions related to
participant’s attitudes towards asthma treatment
(long-term controllers and quick-relief medications
were assessed separately); and (3) questions related
to their expectations about the asthma treatment. The
questionnaire was designed following a literature
research on surveys conducted (1) in Belgian patients
and (2) in patients from other countries focusing on
the aforementioned topics. An English translation of
the questionnaire and an overview of the consulted
literature are available as an online supplement.
Statistical analysis
Data were collected using quantitative measures and
analyzed using descriptive statistics. Participants indi-
cated their answer on a scale of 0 (fully disagree) to 10
(fully agree). For analysis of the questions concerning
attitude towards and expectations about asthma
treatment, scores of 0–3 were pooled as ‘do not
agree’, and 7–10 as ‘agree’; scores 4–6 were consid-
ered to be neutral. To assess adherence, participants
who scored ≤3 (disagree) on the questions ‘use of
long-term control drug less than prescribed’ or ‘use
of quick-relief drug more than prescribed’ were con-
sidered as adherent, whereas those with a score of
4–10 were considered as non-adherent.
A post hoc statistical analysis was performed to
assess a potential correlation between non-adherence
to long-term controller drugs and non-adherence to
quick-relief drugs, and between treatment duration
(≤5 years vs >5 years) and non-adherence to controller
or quick-relief drugs. These correlations were assessed
using Pearson Chi-square tests. After log-
transformation to account for its skewed distribution,
these correlations were also analyzed considering the
individual treatment duration in a logistic regression
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model and statistical signiﬁcance was tested using the
Wald chi-square test.
Results
Survey participants
The analysis included 80 completed questionnaires
(Figure 1). The mean age of the participants was
48 years (standard deviation: 18, range: 16–87); 51%
were male (Table 1). Overall, regional distribution of
participants was balanced (59% of participants were
from Wallonia). Most participants were followed up
by a physician (53% by a general practitioner, 24% by
a general practitioner and pneumologist, and 17% by
a pneumologist only). Out of the 77 participants who
indicated their smoking status, 46 (60%) were non-
smokers, 18 (23%) were former smokers, and 13
(17%) current smokers (Table 1). All 80 participants
reported taking a long-term controller drug, while 56
participants indicated that they were also using
a quick-relief drug (40 [71%] were using a β2-agonist,
13 [23%] a combined anticholinergic/β2-agonist, and 3
[5%] indicated that they were using a β2-agonist and
a combined anticholinergic/β2-agonist). A complete
treatment overview at baseline can be found in
Supplementary Table 1.
Participants’ perception and knowledge of their
asthma drugs
Overall, the participants had a good comprehension
that controller drugs are intended to prevent the
occurrence of asthma symptoms and complications,
and their long-term daily use should be maintained.
Most participants also indicated that controller drugs
can prevent asthma symptoms, are well tolerated,
and easy to use (Figure 2(a)). Although 49% of parti-
cipants agreed that their controller drugs are safe on
long-term basis, around 20–28% indicated a fear of
side eﬀects concerning long-term daily use of
a controller inhaler, regardless of whether they had
been using the drug for more than, or less than,
20 years.
Figure 1. Participant ﬂow chart.
Abbreviations: ACO, asthma-COPD overlap; COPD, chronic obstructive pulmonary disease.
Table 1. Patients’ characteristics.
Characteristic N
n (%) or mean
(SD)
Mean age (years) at dose 1 ± SD N = 79 48 (18.5)
Male, n (%) N = 80 41 (51)
Time since treatment initiation, year
(SD)
N = 70 18 (16.8)
Smoking habits, n (%) N = 77
Non-smoker 46 (60)
Ex-/Current smokers 31 (40)
Education, n (%) N = 79
Secondary school 19 (24)
Higher diploma 51 (65)
Other 9 (11)
Patients distribution according to
region
N = 80
Vlanderen 33 (41.25)
Antwerpen 3 (3.75)
Vlaamse Brabant 10 (12.50)
Limburg 1 (1.25)
Bruxelles/Brussel 6 (7.50)
West Vlanderen 7 (8.75)
Oost Vlanderen 6 (7.50)
Wallonia 47 (59.78)
Hainaut 18 (22.50)
Brabant wallon 2 (2.50)
Liège 13 (16.25)
Luxembourg 12 (15.00)
Namur 2 (2.50)
Abbreviations: N, total number of available data; (%), number (percen-
tage) of patients; SD, standard deviation.
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Participants had a good comprehension that relie-
ver drugs are intended to relieve asthma symptoms,
act quickly on symptoms, and do not need to be used
daily. The majority of participants also indicated that
reliever drugs are well tolerated (71%) and easy to use
(91%) (Figure 2(b)).
Around 40% of participants considered their con-
troller drug as fast-acting, regardless of whether they
were taking a fast-acting type of drug or not. More
speciﬁcally, 40% of 38 participants using a formoterol-
based treatment considered their controller drug as
fast-acting, compared to 41% of 37 participants using
another type of controller drug.
The percentage of participants who agreed that
the drugs are safe when used on long-term basis
tended to be lower for quick-relief drugs than for
long-term controller drugs (36% vs 49%).
Adherence to therapy
Of the 73 participants with available adherence data
on long-term controller drugs, 33 (45%) were consid-
ered as non-adherent as they used it less often than
prescribed. Of the 54 participants with available
quick-relief drug adherence data, 18 (33%) indicated
that they used it more often than prescribed.
Of the 51 participants with adherence data avail-
able for both long-term and quick-relief drugs, only 21
(41%) reported being adherent to long-term drugs
and using quick-relief drugs as prescribed, while 11
(22%) were non-adherent to long-term drugs and
used quick-relief drugs more than prescribed
(Table 2). The proportion of participants who were
non-adherent to their long-term controller drugs
tended to be higher in participants using quick-relief
drugs more than prescribed (11/17; 65%) than in
those using quick-relief drugs as prescribed (13/34;
38%). The proportion of participants using their quick-
relief drugs more often than prescribed tended to be
higher in long-term drug non-adherent participants
(11/24; 46%) than in long-term drug adherent partici-
pants (6/27; 22%). Thus, there was a trend towards
positive correlation between non-adherence to long-
term drugs and using quick-relief drugs more often
than prescribed, but this trend did not reach statistical
signiﬁcance (p = 0.07).
Of the 65 patients with data available for adherence
to long-term controller drugs as well as treatment dura-
tion, the proportion of non-adherence tended to be
higher for those treated for more than 5 years (23/44;
52%) than for those treated for 5 years or less (8/21;
38%), but without reaching statistical signiﬁcance
(p = 0.28). In contrast, of the 48 patients with data
available for both quick-relief adherence and treatment
duration, the proportion of non-adherence tended to be
lower in participants treated for more than 5 years (9/34;
26%) than for those treated for 5 years or less (7/14;
50%), but also without statistical signiﬁcance (p = 0.12)
(Table 2). This correlation has also been analyzed con-
sidering the individual treatment duration in a logistic
regression model. The probability of long-term non-
compliance tended to increase with the treatment dura-
tion, but without reaching statistical signiﬁcance
(p = 0.42, Wald chi-square test) (Supplementary Figure
1). The probability of quick-relief non-compliance
tended to decrease with the treatment duration, but
again without statistical signiﬁcance (p = 0.11, Wald chi-
square test) (Supplementary Figure 2).
Figure 2. Participants’ perception and knowledge of their controller drugs (A) and quick-relief drugs (B).
Notes: Survey scores 0–3 were grouped as ‘do not agree’, scores 7–10 as ‘agree’. Scores 4–6 were considered to be neutral and are not shown in this
graph.
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We also assessed other characteristics of partici-
pants but no clear discriminating factor predicting
medication adherence was observed (Table 3).
Impact of medication adherence on quality of life
Overall, 23% of participants declared to have been
hospitalized due to asthma at least once, 35%
declared having had at least one day with limited
activities due to asthma in the past week, and 29%
declared having had at least one night in the past
week in which they had been awakened due to
asthma. While suboptimal treatment adherence did
not appear to have an impact on hospitalization due
to asthma (Supplementary ﬁgure 3), the proportion of
participants who had at least one day with limited
activities in the past week tended to be higher for
those who were non-adherent to their controller drug
regimen than for the adherent participants (47%
vs 24%) (Supplementary ﬁgure 4). Similarly, the
proportion of participants who were awakened due
to asthma at least one night in the past week tended
to be higher in non-adherent participants than in
adherent participants (Supplementary ﬁgure 5).
Frequency of medication use
Of the 40 participants who indicated being adherent
to their long-term controller drug (thus, not using this
drug less than prescribed), 38 (95%) answered that
they used their long-term drug regularly. Among the
33 non-adherent participants, 24 (73%) indicated that
they used their controller drug regularly, while 6
(18%) used it only at symptoms.
Of the 54 participants using a quick-relief drug, 13
(24%) indicated using their quick-relief drug regularly,
while 35 (65%) used it at symptoms, 6 (11%) at risk (e.
g. pollen period, winter, sports, important or pro-
longed eﬀorts), and 1 (2%) in case of stress. Of the
13 participants who indicated that they used their
Table 3. Factors assessed as potentially inﬂuencing adherence.
Clusters N
Adherent to long-term con-
troller drug
Non-adherent to long-term con-
troller drug N
Adherent to quick-
relief drug
Non-adherent to quick-
relief drug
All 73 40 (55%) 33 (45%) 54 36 (67%) 18 (33%)
Treatment duration:
≤5 years 21 13 (62%) 8 (38%) 14 7 (50%) 7 (50%)
>5 years 44 21 (48%) 23 (52%) 34 25 (74%) 9 (27%)
Education:
Secondary 49 28 (57%) 21 (43%) 34 23 (68%) 11 (32%)
Higher 23 11 (48%) 12 (52%) 20 13 (65%) 7 (35%)
Smoking:
Ex-/Current
smokers
28 16 (57%) 12 (43%) 20 11 (55%) 9 (45%)
Non-smoker 43 23 (54%) 20 (47%) 33 24 (73%) 9 (27%)
≤15 pack-years 10 7 (70%) 3 (30%) 8 4 (50%) 4 (50%)
>15 pack-years 17 8 (47%) 9 (53%) 12 7 (58%) 5 (42%)
Notes: A pack-year is equal to smoking 1 pack per day for 1 year.
Abbreviations: N, number of participants in the respective category.
Table 2. Adherence to therapy.
A. Correlation between adherence to quick-relief drug and to long-term controller drug (N = 51)
Adherent to long term:
n = 27
Non-adherent to long term:
n = 24 p Value
Adherent to quick-relief: n = 34 21 13
Non-adherent to quick-relief: n = 17 6 11
Pearson Chi-square 0.07
B. Correlation between treatment duration and adherence to long-term controller drug (N = 65)
Adherent to long term:
n = 34
Non-adherent to long term:
n = 31
p Value
Treatment ≤5 years: n = 21 13 (62%) 8 (38%)
Treatment >5 years: n = 44 21 (48%) 23 (52%)
Pearson Chi-square 0.28
C. Correlation between treatment duration and adherence to quick-relief drug (N = 48)
Adherent to quick relief:
n = 32
Non-adherent to quick relief:
n = 16
p Value
Treatment ≤5 years: n = 14 7 (50%) 7 (50%)
Treatment >5 years: n = 34 25 (74%) 9 (26%)
Pearson Chi-square 0.12
Notes: Adherence to quick-relief drugs was based on the question ‘Do you use quick-relief drug more than prescribed?’ Adherence to long-term drugs
was based on the question ‘Do you use long-term drug less than prescribed?’ Adherent participants were those with a score ≤3 (disagree), non-
adherent participants those with a score of 4–10.
Abbreviations: N, number of participants with answers available to assess the speciﬁed correlation; n, number of participants in the speciﬁed
category.
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quick-relief drug regularly, 8 (62%) had declared being
adherent to their medication (thus, not using the
quick-relief drug more than prescribed). The charac-
teristics of these 13 participants were as follows: 9
(69%) were smokers, 11 (85%) had a secondary
diploma as highest education level, and their mean
age was 55 years (standard deviation: 16, range:
25–77). Additionally, 9 (69%) of these 13 participants
were not using a fast-acting type of controller drug,
11 (85%) reported using their long-term control drug
regularly, and 7 (54%) were followed up by a general
practitioner only. Concerning asthma symptoms and
impact on their quality of life, 4/13 (31%) declared
having already been hospitalized due to asthma, 6/
12 (50%) declared to have been awakened at night
due to asthma in the past week, and 5/11 (46%)
reported limitations in activities due to asthma.
Discussion
In the survey described in this manuscript, we aimed
to understand the attitude of Belgian asthma
patients towards their medication and their treat-
ment expectations. The survey participants generally
appeared positive about their long-term controller
drugs; the majority agreed with statements that
such therapy is able to prevent asthma symptoms
(74%), is well tolerated (77%), and easy to use (86%).
This seems to be an improvement when compared
to a Belgian assessment performed in 1997, which
reported that 48% of the patients had a negative
perception about ICS, either believing that ICS lacked
eﬃcacy or being concerned about the safety of the
therapy [17]. Findings of other international studies
were similar to our study. When questioned about
attitudes towards inhaler devices, most participants
in an Italian survey tended to have positive opinions
regarding safety, reliability, eﬀectiveness, ease of use,
and practicality [18]. In a survey in the US, more than
85% of patients were satisﬁed with the ease of use
and eﬀectiveness of their current treatment, as well
as with the medication’s time to onset, safety, and
dosing frequency. It is not speciﬁed, however, if the
treatment were inhalers [11].
Despite the generally positive opinions, approxi-
mately one-fourth of our participants indicated
a fear of side eﬀects concerning long-term daily use
of a controller inhaler. In other studies, a substantial
number of patients reported that they were con-
cerned about possible side eﬀects of regular therapy
with corticosteroids, or that they disliked the idea of
using an inhaled steroid [12,19–25]. The belief that
constant use of respiratory drugs is unhealthy has
been found to correlate with accidental as well as
intentional interruption of ICS therapy, and with less
frequent use of ICS upon symptom improvement [12].
Partridge et al. [26] reported that more than half of
the assessed patients from 11 countries (including
Belgium) across 3 continents were concerned about
taking too much controller medication at times when
their symptoms were less prominent or absent.
Moreover, patients preferred to increase the use of
short-acting β2-agonists, and not of ICS, when their
asthma symptoms worsened [26]. Our survey revealed
that non-adherence to long-term controller drugs
tended to be higher in participants who used quick-
relief drugs more than prescribed, suggesting that
patients over-rely on short-acting relievers in prefer-
ence to their maintenance ICS. Surprisingly, medica-
tion adjustment according to symptoms was also
reported by patients who agreed that their controller
inhaler was necessary even when they were not hav-
ing problems with their asthma [21]. In our survey,
among the 33 participants who used their long-term
controller drug less than prescribed, 6 indicated using
the drug at symptoms instead of regularly. In further
studies, it could be interesting to compare the parti-
cipant’s statements on actual inhalations per day and
number of inhalers used per year with standard regi-
mens in terms of adherence.
In our survey, suboptimal adherence was not asso-
ciated with an increased rate of hospitalization due to
asthma (which could, among others, be attributed to
the small sample size), but there was a trend for
increased nightly awakenings and a limitation in activ-
ities due to asthma.
Most participants had good comprehension that
reliever drugs are intended to relieve asthma symp-
toms, act quickly on symptoms, and do not need to
be used daily. For some patients, rescue medications
may also be taken before a known trigger (e.g. exer-
cise) to prevent asthma symptoms; such preventive
use may have prompted certain participants to agree
with statements about quick-relief drugs such as ‘des-
tined to prevent asthma complications’.
In an international survey including Belgian
patients, most patients reported to be dissatisﬁed
with the currently available therapies, particularly
regarding the side-eﬀect proﬁles, and believed there
was a need for new treatment options. The majority
of patients indicated immediate relief from symptoms
as the most desirable trait of asthma medication [26].
In our survey, approximately 40% of participants con-
sidered their controller drug as being fast-acting.
While most patients used their controller drug in
a ﬁxed combination with long-acting β2-agonist
(mainly formoterol, which is characterized by a rapid
onset on drug eﬀect), the perception of long-term
controller drugs as being fast-acting was not inﬂu-
enced by the type of treatment that the participant
was using at the time of the questionnaire (i.e., actu-
ally being a fast-acting type, or not). This could be due
to the fact that ‘fast-acting’ was not precisely deﬁned
in the questionnaires; it is possible that 1 h is
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perceived as fast-acting, while this is not deﬁned as
such by medical personnel (fast-acting drugs typically
have an eﬀect within 10 min). An increasing length of
time with airway problems has been reported to
decrease the odds of taking the medication as pre-
scribed [19]. Moreover, long disease duration has
been associated with beliefs that disease control was
driven by chance (i.e. not under their own control)
[27]. In our survey, the proportion of non-adherence
to long-term controller drugs tended to be higher for
participants treated for more than 5 years than for
those treated for 5 years or less, but without reaching
statistical signiﬁcance.
While the proportion of participants in our survey
who did not use a quick-relief drug may appear high
(21%), 10 of these 17 participants were using a fast-
acting type of controller drug (e.g. ICS plus long-
acting β2-agonist such as formoterol) and, thus,
might have been advised to use that drug also as
rescue therapy. The fact that some controller drugs
can also be used as relief drugs (i.e. formoterol-based
ICS combinations), may have inﬂuenced the partici-
pants’ answer concerning controller drugs; in addition
to control purposes, they may also have pointed
towards the rescue use of their drug (for example,
answering ‘destined to relieve asthma symptoms’).
Of the 13 participants who indicated regular use of
their quick-relief drugs, the majority were smokers,
had no higher education, and their mean age was
55 years. These characteristics resemble the proﬁle
of COPD patients, suggesting that these patients
may suﬀer from asthma-COPD overlap rather than
purely asthma. Of these 13 participants, 8 (62%) had
declared not using their quick-relief drug more than
prescribed and were thus considered adherent to
their medication; this contradicts their statement of
regular quick-relief drug use, as these drugs are not
destined for regular use. These patients were more
likely to have been awakened at night or have had
limitations in activities due to asthma than the overall
population of participants.
Limitations of this study include the small sample
size, as the number of participants was considerably
lower than anticipated. A potential explanation may
be the fact that the questionnaire was too long to
allow completion in the pharmacy; therefore, most
patients took the questionnaire home and not all of
them brought them back to the pharmacy. Due to the
low response rate, it was not possible to separate
adolescents and adults who may have other expecta-
tions and feelings about their disease and treatment.
The assessment of statistical signiﬁcance was only
assessed post hoc for a limited number of compari-
sons, and the fact that none of the comparisons
reached signiﬁcance is likely due to the low number
of survey participants and limited statistical power.
Moreover, we evaluated only patients who came to
the pharmacy, and only a small subset of patients
coming to the pharmacies completed and returned
their questionnaire; this may have caused a bias
towards more adherent patients. Using quick-relief
drugs less often than prescribed has been categorized
as ‘adherent’, while it may have limited patients in
performing activities. Finally, in the survey, the diag-
nosis of asthma was used as mentioned by the parti-
cipant on the questionnaire; thus, we had no
conﬁrmation from a healthcare provider, and we also
did not have any insight in the proportion of patients
with diﬀerent levels of asthma severity. A large pro-
portion of participants declared that they were not
limited in activities during the day, nor had night-time
symptoms, which indicates that these were rather
well-controlled patients.
Conclusion
The results of our survey indicated that the majority of
Belgian asthma patients had relevant knowledge and
positive opinions about their long-term controller and
quick-relief medications. Nevertheless, about a quarter
of participants indicated a fear of side eﬀects concerning
long-term daily use of a controller inhaler. Thus, the fact
that ICS are considered safe for long-term use and
become more eﬃcient with long-term daily use may
need to be further stressed by healthcare providers.
Education of the patients remains a challenge and
should be reinforced. Adherence to both long-term
controller therapy and quick-relief drugs was often
found to be suboptimal – in terms of poor adherence
to controller medication and overuse of reliever medica-
tion – which aﬀected asthma control and quality of life.
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